Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | TSHR | P16473 | 6/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | APP | P05067 | 5/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triethylene Glycol SCHEMBL16394863 | 1.00 | MEN1 (0.79) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL6249482 | 1.00 | MEN1 (0.79) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL421335 | 0.96 | MEN1 (0.85) | MEN1KMT2ATSHRMAPK1THRB | |
| Tetraethylene Glycol SCHEMBL2541664 | 0.96 | MEN1 (0.85) | MEN1KMT2ATSHRMAPK1THRB | |
| Di(Hydroxyethyl)Ether SCHEMBL11126816 | 0.96 | TSHR (0.77) | MEN1KMT2ATSHRMAPK1THRB | |
| Hexaethylene Glycol SCHEMBL9719640 | 0.96 | MEN1 (0.85) | MEN1KMT2ATSHRMAPK1THRB | |
| Di(Hydroxyethyl)Ether SCHEMBL6576238 | 0.96 | TSHR (0.77) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL4603067 | 0.96 | MEN1 (0.85) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL21384854 | 0.96 | MEN1 (0.85) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL1023036 | 0.93 | MEN1 (0.92) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4029508-A1 | TREATMENT OF CANCER USING TLR9 AGONISTS AND CHECKPOINT INHIBITORS | Idera Pharmaceuticals, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3204040-B1 | TREATMENT OF CANCER USING TLR9 AGONISTS AND CHECKPOINT INHIBITORS | IDERA PHARMACEUTICALS INC (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210340544-A1 | TLR9 MODULATORS FOR TREATING CANCER | IDERA PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3213770-B1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | IDERA PHARMACEUTICALS INC (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2020081986-A1 | TLR9 MODULATORS FOR TREATING CANCER | IDERA PHARMACEUTICALS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20200101102-A1 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | IDERA PHARMACEUTICALS, INC. (US) | 2020-04-02 | — | — | US | disclosed |
| US-20180023085-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | IDERA PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-20170274004-A1 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | IDERA PHARMACEUTICALS INC (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170268006-A1 | TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF | IDERA PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| EP-3213770-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | Idera Pharmaceuticals, Inc. (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-1962909-A2 | IMMUNOSTIMULATORY ACTIVITY OF PALINDROMIC IMMUNE MODULATORY OLIGONUCLEOTIDES (IMO TM) CONTIAINING DIFFERENT LENGTHS OF PALINDROMIC SEGMENTS | Idera Pharmaceuticals, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080171712-A1 | At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators | IDERA PHARMACEUTICALS, INC. | 2008-07-17 | — | — | US | disclosed |
| EP-1934239-A2 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | Idera Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080089883-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | IDERA PHARMACEUTICALS, INC. | 2008-04-17 | — | — | US | disclosed |
| WO-2007117686-A2 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | IDERA PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070219153-A1 | Immunostimulatory activity of immune modulatory oligonucleotides (IMOtm) containing different lengths of palindromic segments | IDERA PHARMACEUTICALS. INC. | 2007-09-20 | — | — | US | disclosed |
| WO-2007075626-A2 | IMMUNOSTIMULATORY ACTIVITY OF PALINDROMIC IMMUNE MODULATORY OLIGONUCLEOTIDES (IMO TM) CONTIAINING DIFFERENT LENGTHS OF PALINDROMIC SEGMENTS | IDERA PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007047396-A2 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | IDERA PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-5191123-A | Catalytic decarboxylation with a metal oxide catalyst | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1993-03-02 | — | — | US | disclosed |
| EP-0478076-A2 | Processes for the preparation of hydroxyl-containing compounds | UNION CARBIDE CHEMICALS AND PLASTICS COMPANY, INC. (US) | 1992-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170268006-A1 | TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF | TLR9, TLR3, TLR7 | MEN1 4548/4885KMT2A 1218/4885TSHR 772/4885 |
| US-20200101102-A1 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | TLR9, TLR3, TLR7 | MEN1 2325/4885KMT2A 236/4885TSHR 541/4885 |
| US-20080089883-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | TLR3, TLR9, TLR5 | MEN1 4634/4885KMT2A 2310/4885TSHR 433/4885 |
| US-20210340544-A1 | TLR9 MODULATORS FOR TREATING CANCER | PDCD1LG2, TLR9, CD274 | MEN1 4212/4885KMT2A 209/4885TSHR 921/4885 |
| US-20180023085-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | TLR3, TLR9, TLR5 | MEN1 4634/4885KMT2A 2310/4885TSHR 433/4885 |
| US-20080171712-A1 | At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators | TLR8, TLR7, TLR9 | MEN1 4729/4885KMT2A 1615/4885TSHR 1931/4885 |
| US-20170274004-A1 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | TLR9, TLR3, TLR7 | MEN1 2325/4885KMT2A 236/4885TSHR 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.